Journal article · 2026 · Open access
Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study
The Lancet Infectious Diseases · Published 1 October 2026 · DOI 10.1016/s1473-3099(26)00478-0
In brief
“Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study” is a 2026 journal article by Mulenga Mwenda and 32 co-authors, published in The Lancet Infectious Diseases. OpenAlex counts 2 citations as of 16 November 2026, which puts it in the top 5% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at The Lancet Infectious Diseases.
- Citations
- 2
- Most cited in
- 2026 (2)
- Field-weighted impact
- 8.96
- References
- 32
- Authors
- 33
Abstract
BACKGROUND: Artemisinin derivatives are central to first-line treatment of both uncomplicated and severe Plasmodium falciparum malaria. Emerging artemisinin partial resistance in east Africa threatens to spread across the continent. METHODS: In two cross-sectional studies conducted across the ten provinces of Zambia in 2024, we genotyped the artemisinin resistance-associated gene Pfkelch13. Children aged 6-72 months were recruited from randomly selected households in the first study, and patients 6 months or older presenting with malarial symptoms at 100 selected health facilities were recruited in the second study. In Kaoma, western Zambia, we recruited patients aged 12 months or older with microscopically confirmed P falciparum infection and a positive rapid diagnostic test. We evaluated the association between Pfkelch13 genotype and day 3 parasite positivity following treatment with artemisinin-based combination therapy, as well as ex-vivo parasite susceptibility to dihydroartemisinin (the active metabolite of artemisinin). We also assessed longitudinal changes in Pfkelch13 mutation prevalence in Kaoma using isolates collected during therapeutic efficacy studies and community surveys conducted from 2018 to 2026. FINDINGS: We identified a novel mutation, Pfkelch13 A724E, in 113 (52%) of 217 isolates (95% CI 45-59) from Western Province, 94 (51%) of 184 isolates (95% CI 44-59) from North-Western Province, and 229 (11·7%) of 1949 isolates countrywide. In Kaoma, 28% (21 of 75 [95% CI 18-40]) of patients carrying Pfkelch13 A724E mutant parasites before treatment were parasite-positive on day 3, compared with 0% (zero of 23; [0-15]) of patients with the wild-type allele (p=0·0026). Within the patients who were positive at day 3, the proportion of A724E mutant parasites increased significantly after treatment (p=0·0039). The prevalence of Pfkelch13 A724E in Kaoma increased steadily from 0% (0 of 15 isolates [95% CI 0-22]) in 2018 to 79% (132 of 167 [73-85]) in 2026. No significant ex-vivo growth inhibition was observed in Pfkelch13 A724E parasites after dihydroartemisinin exposure. INTERPRETATION: A novel Pfkelch13 mutation clinically associated with partial resistance to artemisinin is spreading in Zambia. Additional clinical evaluations are urgently needed in the region. FUNDING: The Gates Foundation (INV-048316).
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Mwenda, M., Oliveira, R., Mambwe, B., Chiyesu, C., Bohmeier, B., Mosler, K., Phiri, M., Sinyoolo, A., Chiposa, V., Sichone, T., Munsanje, M., Ilunga, M., Chirwa, C., Mwape, I., Mumba, D., Coppée, R., Stoica, M.-A., Veiga, M. I., DRAKELEY, C. J., . . . Hendry, J. A. (2026). Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00478-0
MLA 9
Mwenda, Mulenga, et al. “Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study.” The Lancet Infectious Diseases, 2026. https://doi.org/10.1016/s1473-3099(26)00478-0.
Chicago
Mwenda, Mulenga, Rafael Oliveira, Brenda Mambwe, Carol Chiyesu, Bernd Bohmeier, Karolina Mosler, Miller Phiri, et al. 2026. “Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study.” The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00478-0.
Harvard
Mwenda, M. et al. (2026) ‘Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study’, The Lancet Infectious Diseases. doi:10.1016/s1473-3099(26)00478-0.
IEEE
M. Mwenda et al., “Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study,” The Lancet Infectious Diseases, 2026, doi: 10.1016/s1473-3099(26)00478-0.
BibTeX
@article{mwenda2026evidence,
title = {{Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study}},
author = {Mwenda, Mulenga and Oliveira, Rafael and Mambwe, Brenda and Chiyesu, Carol and Bohmeier, Bernd and Mosler, Karolina and Phiri, Miller and Sinyoolo, Andy and Chiposa, Virginia and Sichone, Tupilwe and Munsanje, Memory and Ilunga, Mathews and Chirwa, Chitundu and Mwape, Innocent and Mumba, Donald and Coppée, Romain and Stoica, Maria-Alexandra and Veiga, María Isabel and DRAKELEY, CHRIS J. and Pearson, Richard D. and Verity, Robert and Chirwa, Jacob and Mockenhaupt, Frank P. and van Loon, Welmoed and Portugal, Sílvia and Simulundu, Edgar and Bwalya, Stephen and Miller, John M and Chilengi, Roma and Fanaka, Charles and others},
journal = {The Lancet Infectious Diseases},
year = {2026},
doi = {10.1016/s1473-3099(26)00478-0},
url = {https://doi.org/10.1016/s1473-3099(26)00478-0}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Plasmodium falciparum
- Pfkelch13
- artemisinin-based combination therapy
- malaria treatment efficacy
- Zambia
- East Africa
- molecular epidemiology
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Mwenda, M., Oliveira, R., Mambwe, B., Chiyesu, C., Bohmeier, B., Mosler, K., Phiri, M., Sinyoolo, A., Chiposa, V., Sichone, T., Munsanje, M., Ilunga, M., Chirwa, C., Mwape, I., Mumba, D., Coppée, R., Stoica, M.-A., Veiga, M. I., DRAKELEY, C. J., . . . Hendry, J. A. (2026). Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00478-0
How many times has this paper been cited?
2 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at The Lancet Infectious Diseases: sign in and open the full text from this page.
Who wrote this paper?
Mulenga Mwenda, Rafael Oliveira, Brenda Mambwe, Carol Chiyesu, Bernd Bohmeier, Karolina Mosler, Miller Phiri, Andy Sinyoolo, Virginia Chiposa, Tupilwe Sichone, Memory Munsanje, Mathews Ilunga and 21 more.
What is the DOI of this paper?
10.1016/s1473-3099(26)00478-0, permanently at https://doi.org/10.1016/s1473-3099(26)00478-0. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.